Nature Reviews Cardiology最新文献_第8页

Solving the mystery of vaccine-induced immune thrombocytopenia and thrombosis 解决疫苗诱导的免疫性血小板减少症和血栓形成之谜。

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-18 DOI: 10.1038/s41569-026-01279-7

Julie Rayes, Jagadeesh Bayry

引用次数: 0

Injectable magnetofluid achieves complete, thrombus-free LAA occlusion in preclinical models 注射磁流体在临床前模型中实现完全无血栓的LAA闭塞。

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-17 DOI: 10.1038/s41569-026-01280-0

Irene Fernández-Ruiz

引用次数: 0

Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events? 解决Lp(a)假设：降低Lp(a)会降低心血管事件的风险吗？

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-17 DOI: 10.1038/s41569-026-01278-8

Marlys L. Koschinsky, Michael B. Boffa

引用次数: 0

Cardiac lymphatic dysfunction and repair in cardiovascular disease. 心淋巴功能障碍与心血管疾病的修复。

IF 49.6 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-12 DOI: 10.1038/s41569-026-01271-1

Ebba Brakenhielm

{"title":"Cardiac lymphatic dysfunction and repair in cardiovascular disease.","authors":"Ebba Brakenhielm","doi":"10.1038/s41569-026-01271-1","DOIUrl":"https://doi.org/10.1038/s41569-026-01271-1","url":null,"abstract":"The field of cardiac lymphatic research has expanded considerably over the past decade. Clinical studies have uncovered lymphatic remodelling in a wide range of cardiovascular diseases, and experimental research has demonstrated that these structural alterations often lead to dysfunction of lymphatic transport. Given the vital physiological role of lymphatics, insufficient lymphatic drainage can affect several aspects of cardiac pathophysiology, including myocardial fluid balance, the immune microenvironment, collagen turnover and lipid handling. In this Review, current knowledge on cardiac lymphatics is summarized, including the structural and molecular specializations underlying their diverse homeostatic functions, and how these features can be altered in cardiovascular diseases. The latest research on the effects of inflammation on lymphatics is presented, together with the mechanisms by which lymphatics modulate immunity. The regulation of cardiac lymphangiogenesis is discussed, including accumulating evidence of immune cell-lymphatic crosstalk in the heart, the role of metabolic and biomechanical stimulation of lymphangiogenesis, and examples of experimental approaches to therapeutic lymphangiogenesis and their current limitations. Finally, areas for future research are highlighted, including the translation of lymphatic imaging and lymphangiogenic therapies to the clinic for patients with cardiovascular disease.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"30 1","pages":""},"PeriodicalIF":49.6,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiphospholipid antibodies and cardiovascular thrombosis. 抗磷脂抗体和心血管血栓。

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-10 DOI: 10.1038/s41569-026-01269-9

Sina Rashedi, Hannah Leyva, Saman A Siddiqui, Syed Bukhari, Mariana B Pfeferman, Nathan W Watson, Francisco Ujueta, Mehrdad Zarghami, Bassil Bacare, Yogendra Kanthi, David Jimenez, Manuel Monreal, Deborah M Siegal, Geoffrey D Barnes, John W Eikelboom, Michelle L O'Donoghue, Christian T Ruff, Mattia Galli, Brittany N Weber, Samuel Z Goldhaber, Sacha Uljon, Saskia Middeldorp, Renato D Lopes, David A Garcia, Gregory Y H Lip, Jeffery I Weitz, Jean M Connors, Harlan M Krumholz, Jason S Knight, Giuseppe Lippi, Mitchell S V Elkind, Mary Cushman, Karen H Costenbader, Gregory Piazza, Behnood Bikdeli

{"title":"Antiphospholipid antibodies and cardiovascular thrombosis.","authors":"Sina Rashedi, Hannah Leyva, Saman A Siddiqui, Syed Bukhari, Mariana B Pfeferman, Nathan W Watson, Francisco Ujueta, Mehrdad Zarghami, Bassil Bacare, Yogendra Kanthi, David Jimenez, Manuel Monreal, Deborah M Siegal, Geoffrey D Barnes, John W Eikelboom, Michelle L O'Donoghue, Christian T Ruff, Mattia Galli, Brittany N Weber, Samuel Z Goldhaber, Sacha Uljon, Saskia Middeldorp, Renato D Lopes, David A Garcia, Gregory Y H Lip, Jeffery I Weitz, Jean M Connors, Harlan M Krumholz, Jason S Knight, Giuseppe Lippi, Mitchell S V Elkind, Mary Cushman, Karen H Costenbader, Gregory Piazza, Behnood Bikdeli","doi":"10.1038/s41569-026-01269-9","DOIUrl":"https://doi.org/10.1038/s41569-026-01269-9","url":null,"abstract":"Antiphospholipid antibodies (aPL) are directed against phospholipids and phospholipid-binding proteins. Laboratory assays used to detect aPL include serological tests for aPL against β2-glycoprotein 1, cardiolipin and other molecules, as well as functional assays for lupus anticoagulant. The presence of aPL can lead to endothelial dysfunction or a hypercoagulable state through prothrombotic and antifibrinolytic mechanisms. These processes, often in conjunction with a 'second hit', such as trauma, surgery, or other causes of hypercoagulability or stasis, can lead to venous or arterial thrombosis. The thrombotic risk associated with aPL is best recognized in thrombotic antiphospholipid syndrome, characterized by a persistently positive test for lupus anticoagulant or seropositivity for aPL associated with venous, arterial or microvascular thrombosis. However, aPL seropositivity and its clinical effect on thrombotic events have been increasingly recognized in a broader group of individuals who do not meet traditional research criteria for thrombotic antiphospholipid syndrome. In this Review, we provide an overview of the evidence related to aPL seropositivity in individuals with or without previous thrombosis and the clinical relevance of aPL seropositivity in predicting the risk of thrombotic cardiovascular events. We discuss potential management strategies and identify key knowledge gaps that warrant further research.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":44.2,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147434110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ANGPTL3-lowering strategies to address residual cardiovascular risk 降低angptl3的策略解决剩余心血管风险。

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-10 DOI: 10.1038/s41569-026-01273-z

Farzahna Mohamed, Frederick J. Raal

引用次数: 0

The City Heartbeat Index as a benchmarking tool for urban cardiovascular health 城市心跳指数作为城市心血管健康的基准工具。

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-03 DOI: 10.1038/s41569-026-01267-x

Amanda Stucke, Craig K. Cassidy, Anelia Boshnakova, Miranda Baxa, Alicia White, Amam Mbakwem, Borjana Pervan, Finn-Jarle Rode, Fausto Pinto, Daniel Pineiro, Jagat Narula

引用次数: 0

Author Correction: The effects of skeletal muscle and adipose tissue on outcomes in patients with heart failure 作者更正：骨骼肌和脂肪组织对心力衰竭患者预后的影响。

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-03-02 DOI: 10.1038/s41569-026-01272-0

Wolfram Doehner, Henning T. Langer

引用次数: 0

Understanding atrial failure: from diagnosis to clinical implications 了解心房衰竭：从诊断到临床意义。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-02-27 DOI: 10.1038/s41569-026-01266-y

Bryce Alexander, Eugene Braunwald, Antoni Bayés-de-Luna, Aws Almufleh, Antoni Bayés-Genís, Adrian Baranchuk

{"title":"Understanding atrial failure: from diagnosis to clinical implications","authors":"Bryce Alexander, Eugene Braunwald, Antoni Bayés-de-Luna, Aws Almufleh, Antoni Bayés-Genís, Adrian Baranchuk","doi":"10.1038/s41569-026-01266-y","DOIUrl":"10.1038/s41569-026-01266-y","url":null,"abstract":"Atrial failure is an emerging clinical syndrome that results from an underlying atrial cardiomyopathy and is characterized by impaired atrial haemodynamic and/or electrical function that is sufficient to cause symptoms, adverse clinical outcomes or both. Similar to ventricular cardiomyopathy, atrial cardiomyopathy refers to a structural, functional and/or electrophysiological tissue abnormality, whereas atrial failure denotes the stage at which it manifests clinically. Atrial failure can be classified as primary, when driven by intrinsic atrial pathology, or secondary, when atrial dysfunction arises from sustained haemodynamic or electrical stress imposed by ventricular, valvular or systemic disease. Increasing evidence indicates that atrial failure might not be merely a bystander, but a key determinant of symptoms and prognosis in cardiovascular conditions. Atrial failure can act as a primary driver of heart failure with preserved ejection fraction, promote atrial arrhythmias through adverse electrical remodelling, and potentially increase thromboembolic risk independently of atrial fibrillation. In this Review, we detail the pathophysiological mechanisms and clinical phenotypes of atrial failure and highlight the role of multimodality imaging in diagnosing and phenotyping atrial cardiomyopathy and clinical atrial failure. Finally, we summarize emerging therapeutic strategies aimed at potentially reversing atrial adverse remodelling and discuss future directions for integrating atrial failure into clinical practice. Atrial failure is an emerging clinical syndrome that results from an underlying atrial cardiomyopathy and manifests with clinical symptoms. In this Review, Baranchuk and colleagues detail the pathophysiological mechanisms, clinical phenotypes and multimodality imaging of atrial failure as well as emerging therapeutic strategies to reverse atrial remodelling.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":"23 9","pages":"631-643"},"PeriodicalIF":50.2,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effects of skeletal muscle and adipose tissue on outcomes in patients with heart failure 骨骼肌和脂肪组织对心力衰竭患者预后的影响

IF 44.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-02-24 DOI: 10.1038/s41569-026-01268-w

Wolfram Doehner, Henning T. Langer

引用次数: 0